

Dechra Pharmaceuticals PLC
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

10 September 2021

Dear Shareholder,

I am writing to explain in detail the matters to be dealt with at this year's Annual General Meeting (Meeting) to be held at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 9.30 am on 21 October 2021. The formal notice of the Meeting, which is set out on pages 6 to 8 of this document (Notice), sets out the business to be considered at the Meeting. The purpose of this letter is to provide you with further details about those items of business.

If you have requested a hard copy of the Annual Report and Accounts, it should be enclosed with this Notice and the Proxy Form for the Meeting. If you receive your Annual Report and Accounts electronically or did not return the Shareholder Communication Response sent to you in September 2020, please accept this letter as notification that the Annual Report and Accounts and associated documents have now been published on the Investor Relations section of our website (www.dechra.com).

Safely attending the Annual General Meeting

No business will be considered at the Meeting other than the resolutions dealt with in this Notice.

Should you wish to attend the Meeting in person, please pre-register your intention to attend by emailing companysecretarial@dechra.com (please state "Dechra Pharmaceuticals PLC: AGM" in the subject line of the email) by 15 October 2021. Please include your full name and Shareholder Reference Number, which can be found on the proxy card, your share certificate or on the Equiniti Portal. This will enable us to put in place the requisite measures which we may need to introduce to meet any potential government-mandated Covid-19 restrictions. We may ask you to complete a visitor questionnaire which includes a self-declaration that you have either had two vaccinations at least two weeks before the Meeting or can show that you have had a negative lateral flow test no older than 48 hours before the Meeting or a positive PCR test within the past six months before the meeting.

We will continue to monitor the impact of the pandemic, and you should monitor the Company's website (www.dechra.com/investors/shareholder-information/shareholder-meetings) and regulatory news announcements for any Meeting updates.

This year we will be offering an online Annual General Meeting experience for the first time. You will have the opportunity to listen to the proceedings of the Meeting via https://brrmedia.news/Dechra_AGM21. Please note that joining remotely via https://brrmedia.news/Dechra_AGM21 does not constitute attendance at the Meeting and you will not be able to vote at the Meeting. Therefore you should submit your votes in the normal way, via proxy. Note 24 of this Notice contains an online shareholder guide.

If the chairman of the Meeting is appointed as proxy, they will vote in accordance with any instructions given to them. If the chairman of the Meeting is given discretion as to how to vote, they will vote in favour of each of the resolutions to be proposed at the Meeting.

We are proposing to put all resolutions at the Meeting by the way of a poll rather than a show hands. This will allow the votes of all shareholders to be counted.

As we did last year, we will offer a facility should shareholders wish to put questions to the Board. These can be submitted by email to CompanySecretarial@dechra.com (please state "Dechra Pharmaceuticals PLC: AGM" in the subject line of the email and include your Shareholder Reference Number (as detailed on your proxy card, share certificate or on the Equiniti Portal)). These questions must be submitted by 19 October 2021. The Board will seek to respond to questions which are put forward in advance of the Meeting during the Meeting and/or by publishing written responses on the Investors section of our website after the Meeting together with results of voting.

Explanation of Resolutions

This year, shareholders will be asked to approve 21 resolutions. Resolutions 1 to 16 (inclusive) and Resolution 21 are proposed as ordinary resolutions requiring the approval of a simple majority of the votes cast at the Meeting. Resolutions 17 to 20 (inclusive) are proposed as special resolutions requiring the approval of 75% of the votes cast at the Meeting.

The Annual Report and Accounts (Resolution 1)

Shareholders will be asked to receive the Company's accounts, Strategic Report, Directors' Report and Auditor's Report for the year ended 30 June 2021.

Directors' Remuneration Report (Resolution 2)

The Company is required to seek shareholders' approval of the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) and a statement by the Remuneration Committee Chairman (together, the Directors' Remuneration Report). The Directors' Remuneration Report describes how the Company's Directors' Remuneration Policy has been implemented during the previous financial year and will be implemented in the current financial year, and this report can be found on pages 119 to 141 of the Annual Report and Accounts. The vote is advisory in nature and is not binding; the Directors' entitlements to remuneration are not conditional upon this Resolution being passed.

The Directors' Remuneration Policy itself was approved by shareholders at last year's Annual General Meeting held on 27 October 2020 and, unless amended, is only required to be approved once every three years.

Final Dividend (Resolution 3)

A final dividend of 29.39 pence per ordinary share is recommended by the Directors. Subject to approval at the Meeting, the dividend will be paid on 19 November 2021 to shareholders who are on the Register of Members at the close of business on 29 October 2021. The shares will become ex-dividend on 28 October 2021. An interim dividend of 11.11 pence per ordinary share was paid on 7 April 2021.

Election of Directors (Resolution 4)

Denise Goode was appointed as a Non-Executive Director of the Company on 26 April 2021 and therefore, in line with the Company's Articles of Association, she will offer herself for election by the shareholders at the Meeting.

Denise brings a wealth of financial, commercial and life sciences industry experience, both from her extensive career as a senior executive and from board roles held since 2008. The Board is satisfied that Denise is independent in accordance with the UK Corporate Governance Code 2018 (the Code). The Nomination Committee has considered Denise's commitments and has concluded that she has sufficient time to devote to the role. Her biographical details were set out in the announcement published by the Company on 31 March 2021 and can also be found on page 89 of the Annual Report and Accounts.

Re-election of Directors (Resolutions 5 to 13)

Notwithstanding the Company's Articles of Association, which require just one-third of the Directors to retire by rotation at each annual general meeting, in compliance with the Code all Directors shall stand for annual re-election. All of the Directors who were appointed or re-appointed at the 2020 Annual General Meeting have indicated their willingness to offer themselves for re-election. The Nomination Committee has considered the time commitments of the Non-Executive Directors and has confirmed that they are satisfied that all of the Non-Executive Directors have sufficient time to meet their Board and Committee responsibilities.

The Board is satisfied that all of the Non-Executive Directors are independent and the Chairman was deemed independent on appointment in accordance with the Code. The Board, having considered the mix of skills, knowledge and experience of the Directors, confirms that each Director continues to perform his or her duties effectively, showing integrity and high ethical standards whilst maintaining sound, independent judgement in respect of all decisions taken at both Board and, where applicable, Committee level to ensure the Company's long term sustainable success.

Biographical details for each of the Directors are located on pages 88 and 89 of the Annual Report and Accounts. The review process of the existing Directors and the Company's assessment of independence are described on pages 99, 105, 110 and 111 of the Annual Report and Accounts.

Contribution to Long Term Sustainable Success

The Board have determined that I bring extensive Board level experience across a range of sectors in FTSE 100, FTSE 350 and private equity owned businesses. I have gained extensive knowledge of international businesses which brings a different industry perspective to the Board.

You will have seen the notification in the preliminary results announcement of my intention to step down as Chairman once we have identified and agreed a successor. It has been my privilege and pleasure to work with Ian, his management team and the Board these past five years as Dechra has continued to evolve and grow and deliver great products and services to our customers and strong returns to our shareholders. This is a suitable time for me to leave to devote more time to my family and my other business and charitable activities.

Ian Page brings detailed knowledge and experience of the veterinary pharmaceutical business to his leadership of the Senior Executive Team and the management of the Group. He has led the management team and the Company since 2001, and has played a key role in the development of the Group's growth and strategy. He continues to lead the management team and the implementation and development of the Group's strategy, identifying acquisition opportunities for Board discussion. The Group has completed 20 acquisitions. Ian engages extensively with our major shareholders and brings their viewpoint to Board discussions.

Tony Griffin has over 30 years' experience in the animal health business and has substantial international experience. As the Managing Director of DVP EU, our largest sales and marketing organisation, he can provide a customer and market perspective on Board decisions.

Paul Sandland has over ten years' experience in senior finance roles in Dechra. He brings with him a strong practical understanding of all parts of the Group and its needs, as well as an independence of mind and strong technical, strategic and commercial skills.

Lisa Bright has strategic and operational leadership experience in global market leading pharmaceutical companies gained over her 30 year career in the industry; she is able to provide a customer focus on Board decisions. As the Employee Designated Non-Executive Director she is able to provide an employee's perspective in Board discussions. Her recent external role as executive director brings a different focus to Board discussions.

Julian Heslop has significant financial experience as a result of the senior finance roles he has held in GlaxoSmithKline as well as food, property and brewing sectors over the last 30 years. His in-depth knowledge and expertise in financial and accounting matters combined with significant managerial experience throughout his career allow him to excel in his Audit Committee Chairman role. His financial experience allows him to bring a financial and strategic outlook in Board and Committee discussions.

Ishbel Macpherson has a wealth of listed company experience and provides an understanding of UK corporate governance requirements to the Board. She also has knowledge and understanding of City matters gained over 20 years' experience as an investment banker, specialising in UK mid-market corporate finance, and aids the Board discussions on financing and the financial risks of acquisitions. Ishbel's financial and listed company experience brings an understanding of remuneration matters to her role as Chairman of the Remuneration Committee.

Lawson Macartney is a veterinarian, with post-doctoral training in viral pathobiology and is also trained as a pathologist (FRCPath), with many years of experience in veterinary practice and over 30 years of knowledge gained in the global pharmaceutical industry, he brings a broad perspective to the Board. This knowledge, experience and expertise of product development and commercialisation is invaluable to the Board when analysing acquisition opportunities and when discussing the product development pipeline.

Alison Platt brings extensive experience of leadership in customer-driven organisations across the healthcare, insurance and property sectors as well as international experience. Alison's capabilities and experience both in Executive and Non-Executive roles in FTSE 100 and 350 companies strengthens the Board. Her previous membership of the steering group for the Hampton-Alexander Review provides strategic insights on diversity and inclusion.

Re-appointment of Auditor and Auditor's Remuneration (Resolutions 14 and 15)

The Company is required to appoint an external auditor at each Annual General Meeting at which accounts are laid before the Company, to hold office until the conclusion of the next such meeting.

Resolution 14, on the Audit Committee's recommendation (the Audit Committee having evaluated the effectiveness and independence of the external auditor), proposes the re-appointment of the Company's existing external auditor, PricewaterhouseCoopers LLP, from the conclusion of the Meeting until the conclusion of the next Annual General Meeting at which accounts are presented.

Resolution 15 is a separate resolution which gives authority to the Audit Committee to determine the external auditor's remuneration.

Authority to Allot Equity Securities (Resolution 16)

The Directors may only allot shares in the Company (or grant rights to subscribe for, or to convert any security into, shares in the Company) if they have been authorised to do so by shareholders.

Resolution 16 renews a similar authority given at last year's Annual General Meeting held on 27 October 2020 and is in two parts.

General Allotment of Shares

Part one of Resolution 16 will give the Directors authority to allot shares or to grant rights to subscribe for, or to convert any security into, shares in the Company up to an aggregate nominal amount of £360,725 as reduced by the aggregate nominal amount of any shares allotted or rights granted under part two of Resolution 16 in excess of £360,725. This amount (before any reduction) represents approximately one third of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice.

Rights Issue

In line with guidance issued by the Investment Association, if passed, part two of Resolution 16 will authorise the Directors to allot shares in the Company (and to grant rights to subscribe for, or to convert any security into, shares in the Company) in connection with a rights issue only up to a nominal amount of £721,450 (as reduced by the nominal amount of any shares allotted or rights granted under part one of Resolution 16). This amount (before any reduction) represents approximately two thirds of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice.

If given, these authorities will expire at the conclusion of the Company's next Annual General Meeting or, if earlier, 15 months from the passing of the Resolution. It is the Directors' intention to renew the allotment authorities each year.

The Directors have no current intention to exercise either of the authorities sought under Resolution 16, except under paragraph 16.1 of Resolution 16 to satisfy options under the Company's share option schemes if appropriate and to ensure that the Company has maximum flexibility in managing the Group's resources. The Board would use this authority only if satisfied at the time that it is appropriate to do so to respond to market developments or to take advantage of business opportunities as they arise. The terms of this Resolution are in accordance with the latest institutional guidance (Share Capital Management Guidelines) issued by the Investment Association. If the Directors do exercise this authority, the Directors intend to follow best practice as regards to its use.

As at the date of this Notice, no treasury shares are held by the Company.

Disapplication of Pre-emption Rights (Resolutions 17 and 18)

Resolutions 17 and 18 will be proposed as Special Resolutions which, if passed, will enable the Directors to allot shares for cash or sell treasury shares for cash up to a maximum aggregate nominal amount of £108,216 (which represents approximately 10% of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice) without first having to offer them to existing shareholders in proportion to their existing holdings.

Resolution 17 will empower the Directors to allot shares or sell treasury shares for cash up to an aggregate nominal amount of:

- (i) £721,450 (which represents approximately two thirds of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice) in connection with a rights issue; or
- (ii) £360,725 (which represents approximately one third of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice) in connection with an open offer or other pre-emptive offer,

in each case to ordinary shareholders and to holders of other equity securities (if required by the rights of those securities or the Directors otherwise consider necessary), but (in accordance with normal practice) subject to such exclusions or other arrangements, such as for fractional entitlements and overseas shareholders, as the Directors consider necessary; and

- (iii) in any other case, up to an aggregate nominal amount of £54,108 (which represents approximately 5% of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice).

Resolution 18 increases the Directors' powers under Resolution 17 to allot shares or sell treasury shares for cash (on a non-pre-emptive basis) up to a further aggregate nominal amount of £54,108 (which represents approximately 5% of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice), such that the combined powers under Resolutions 17 and 18 would be £108,216 (which represents approximately ten per cent of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice). The power under Resolution 18 would only be used for the purposes of financing (or refinancing, if such refinancing occurs within six months of the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Pre-Emption Group's Statement of Principles on Disapplying Pre-Emption Rights.

There are no present plans to exercise these powers and, in accordance with the guidelines issued by the Pre-Emption Group, the Directors do not expect to allot shares for cash (or sell treasury shares) on a non-pre-emptive basis pursuant to the authorities in Resolutions 17 and 18: (i) in excess of an amount equal to 5% of the issued share capital of the Company; or (ii) in excess of an amount equal to 7.5% of the issued share capital of the Company within a rolling three-year period, without prior consultation with the Company's shareholders, in each case other than in connection with an acquisition or specified capital investment which is announced contemporaneously with the issue or which has taken place in the preceding six month period and is disclosed in the announcement of the allotment.

If given, the powers in Resolutions 17 and 18 will expire at the conclusion of the Company's next Annual General Meeting or, if earlier, 15 months from the passing of these Resolutions. It is the Directors' intention to renew these powers each year.

Authority to Purchase Ordinary Shares (Resolution 19)

Resolution 19 will be proposed as a Special Resolution for the renewal of the Company's authority to purchase its own shares in the market during the period until the next Annual General Meeting of the Company for up to 10,821,763 shares, representing approximately 10% of the issued ordinary share capital of the Company as at 9 September 2021, being the last practicable date before the publication of this Notice.

The Directors have no current intention of exercising this authority to purchase the Company's ordinary shares, but consider the authority desirable to provide maximum flexibility in the management of the Company's capital base. The Company will only exercise this authority to make such a purchase in the market if the Directors consider it is in the best interests of the shareholders generally to do so and that to do so would result in an increase in earnings per share.

The Company is permitted to hold shares it has purchased in treasury, as an alternative to cancelling them. Shares held in treasury may subsequently be cancelled, sold for cash or used to satisfy options exercised under any of the Company's share schemes.

Whilst held in treasury, the shares are not entitled to receive any dividend or dividend equivalent (apart from any issue of bonus shares) and have no voting rights. The Directors believe it is appropriate for the Company to have the option to hold its own shares in treasury if, at a future date, the Directors exercise this authority in order to provide the Company with additional flexibility in the management of its capital base. The Directors will have regard to investor group guidelines which may be in force at the time of any such purchase, holding or re-sale of shares held in treasury. As at 9 September 2021 (being the last practicable date prior to the publication of this Notice), no shares were held in treasury.

On 9 September 2021 (being the last practicable date prior to the publication of this Notice) there were options over ordinary shares in the capital of the Company representing 0.81% of the Company's issued ordinary share capital as at that date. If the authority to purchase the Company's ordinary shares was exercised in full and those shares were subsequently cancelled, these options would represent 0.90% of the Company's issued and voting ordinary share capital.

If given, this authority will expire at the conclusion of the Company's next Annual General Meeting or, if earlier, 15 months after the passing of the Resolution. It is the Directors' intention to renew this authority each year.

Notice Period for General Meetings (Resolution 20)

Resolution 20 will be proposed as a Special Resolution and would allow the Company to hold general meetings (other than Annual General Meetings) on 14 clear days' notice. Annual General Meetings must always be called with at least 21 clear days' notice but other general meetings of the Company may be called on less notice if shareholders agree to a shorter notice period. The shareholders of the Company approved a resolution to call general meetings (other than Annual General Meetings) on 14 clear days' notice at last year's Annual General Meeting held on 27 October 2020. Resolution 20 seeks approval to renew this right until the Company's next Annual General Meeting, when it is intended that a similar resolution will be proposed.

The shorter notice period would not be used as a matter of routine for such meetings, but only where flexibility is merited by the business of the meeting and is thought to be to the advantage of shareholders as a whole and the matter to be considered is time sensitive. The Company meets the requirement under the Companies Act 2006 that a means of electronic voting must be provided to all shareholders if a general meeting is to be called on less than 21 clear days' notice.

Approve the Rules of the Dechra 2021 Deferred Bonus Plan (Resolution 21)

Shareholders will be asked to approve the Dechra 2021 Deferred Bonus Plan. This plan is being introduced in order to facilitate the deferral of annual bonuses in line with the Company's Directors' Remuneration Policy, which was approved by shareholders at the Company's 2020 Annual General Meeting.

A summary of the principal terms of the new plan is set out in the Appendix to this circular.

Recommendation

The Directors believe that all of the Resolutions to be considered at the Meeting are in the best interests of the Company and its shareholders as a whole. They unanimously recommend that you vote in favour of all of the proposed Resolutions. The Directors will be voting in favour of all of the proposed Resolutions in respect of their own shareholdings in the Company.

Action to be taken

Please complete and return the enclosed Proxy Form so as to reach the Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA no later than 9.30 am on 19 October 2021 (or, if the Meeting is adjourned, no later than 48 hours before the time of any adjourned meeting). The Company also offers all shareholders the right to lodge their proxy vote electronically and details of how to do this can be found in the notes to the Notice and on the front of the enclosed Proxy Form. Completion and lodging of the Proxy Form will not prevent you from attending and voting in person if you so wish (though please ensure that you pre-register your intention to attend in accordance with note 2 to the Notice).

Thank you for your continuing support of our Company.

Yours sincerely and keep safe.

Tony Rice

Non-Executive Chairman

DECHRA PHARMACEUTICALS PLC (THE COMPANY)

NOTICE OF ANNUAL GENERAL MEETING (THE MEETING)

Notice is hereby given that the 2021 Annual General Meeting of the Company will be held at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich CW9 7UA at 9.30 am on 21 October 2021 for the following purposes:

Ordinary Business

To consider and, if thought fit, pass the following resolutions as Ordinary Resolutions.

1. To receive the accounts of the Company for the year ended 30 June 2021, together with the Strategic Report, Directors' Report and the Auditor's Report (the Annual Report).
2. To approve the Directors' Remuneration Report (other than the part that contains the Directors' Remuneration Policy) for the year ended 30 June 2021.
3. To declare a final dividend for the year ended 30 June 2021 of 29.39 pence per ordinary share in the capital of the Company, to be paid on 19 November 2021 to members whose names appear on the Register of Members of the Company as at the close of business on 29 October 2021.
4. To elect Denise Goode as a Director of the Company.
5. To re-elect William Anthony Rice as a Director of the Company.
6. To re-elect Ian Page as a Director of the Company.
7. To re-elect Anthony Griffin as a Director of the Company.
8. To re-elect Paul Sandland as a Director of the Company.
9. To re-elect Lisa Bright as a Director of the Company.
10. To re-elect Julian Heslop as a Director of the Company.
11. To re-elect Ishbel Macpherson as a Director of the Company.
12. To re-elect Lawson Macartney as a Director of the Company.
13. To re-elect Alison Platt as a Director of the Company.
14. To re-appoint PricewaterhouseCoopers LLP as external auditor of the Company to hold office from the conclusion of the Meeting until the conclusion of the next Annual General Meeting of the Company at which accounts be laid.
15. To authorise the Audit Committee to determine the remuneration of the external auditor.

Special Business

To consider and, if thought fit, pass the following Resolutions, of which Resolutions 16 and 21 will be proposed and voted on as Ordinary Resolutions and Resolutions 17 to 20 (inclusive) will be proposed and voted on as Special Resolutions.

16. That, pursuant to section 551 of the Companies Act 2006 (2006 Act), the Directors be generally and unconditionally authorised to exercise all powers of the Company to allot shares in the Company and to grant rights to subscribe for or convert any security into shares of the Company:
 - 16.1 up to an aggregate nominal amount of £360,725 (such amount to be reduced by any allotments or grants in excess of an aggregate nominal value of £360,725 made under paragraph 16.2 of this Resolution), and
 - 16.2 comprising equity securities (as defined in section 560(1) of the 2006 Act) up to an aggregate nominal amount of £721,450 (such amount to be reduced by the aggregate nominal value of any allotments or grants made under paragraph 16.1 of this Resolution) in connection with an offer by way of a rights issue:
 - 16.2.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of ordinary shares held by them; and
 - 16.2.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the Directors otherwise consider necessary,

subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange;

provided that:

- (a) these authorities (unless previously revoked, varied or renewed) shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, at close of business on the date 15 months from the date of the passing of this Resolution;
- (b) the Company is entitled to make offers or agreements before the expiry of such authority, which would or might require shares to be allotted or rights to be granted after such expiry and the Directors shall be entitled to allot shares and grant rights pursuant to any such offer or agreement as if this authority had not expired; and
- (c) the authority is in substitution for all existing unused authorities.

17. That, subject to the passing of Resolution 16 and pursuant to sections 570 to 573 of the 2006 Act, the Directors are generally empowered to allot or make offers or agreements to allot equity securities (as defined in section 560(1) of the 2006 Act) for cash pursuant to the authorities granted by Resolution 16 and/or to sell ordinary shares held by the Company as treasury shares for cash, as if section 561(1) of the 2006 Act did not apply to any such allotment (or sale), provided such power be limited to the allotment of equity securities or sale of treasury shares:

17.1 in connection with an offer of, or invitation to apply for, equity securities (but, in the case of an allotment pursuant to the authority granted under paragraph 16.2 of Resolution 16, such power shall be limited to the allotment of equity securities in connection with an offer by way of a rights issue):

17.1.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of ordinary shares held by them; and

17.1.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the Directors otherwise consider necessary,

subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange; and

17.2 otherwise than pursuant to paragraph 17.1 of Resolution 17, up to an aggregate nominal amount of £54,108, and (unless previously revoked, varied or renewed) this power shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, at close of business on the date 15 months from the date of the passing of this Resolution but, in each case, prior to its expiry the Company may make an offer or agreement which would, or might, require equity securities to be allotted for cash (or treasury shares to be sold) after this power expires and the Directors may allot equity securities (or sell treasury shares) for cash pursuant to any such offer or agreement as if this power had not expired.

This power is in substitution for and shall replace all existing powers which, to the extent unused at the date of this Resolution, are revoked with immediate effect, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.

18. That, subject to the passing of Resolutions 16 and 17 and in addition to any power granted pursuant to Resolution 17, the Directors are generally empowered to allot equity securities (as defined in section 560 of the 2006 Act) for cash pursuant to the authorities granted by Resolution 16 and to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the 2006 Act did not apply to any such allotment or sale, such power be limited to the allotment of equity securities or sale of treasury shares:

18.1 up to an aggregate nominal amount of £54,108; and

18.2 used only for the purposes of financing (or refinancing, if such refinancing occurs within six months of the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre Emption Rights most recently published by the Pre Emption Group prior to the date of this Notice,

and such power shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, at close of business on the date 15 months from the date of the passing of this Resolution, but, in each case, prior to its expiry the Company may make an offer or agreement which would, or might, require equity securities to be allotted or treasury shares to be sold for cash after this power expires and the Directors may allot equity securities or sell treasury shares for cash pursuant to any such offer or agreement as if this power had not expired.

19. That, the Company is generally and unconditionally authorised for the purposes of section 701 of the 2006 Act to make market purchases (as defined in section 693(4) of the 2006 Act) of ordinary shares in the capital of the Company (Shares) from the date this Resolution is passed until the conclusion of the next Annual General Meeting of the Company or, if earlier, at close of business on the date 15 months from the date of the passing of this Resolution, subject to the following conditions:
- 19.1 the maximum number of Shares which may be purchased is 10,821,763 (representing 10% of the Company's issued ordinary share capital);
 - 19.2 the minimum price (exclusive of expenses) which may be paid for a Share is £0.01;
 - 19.3 the maximum price (exclusive of expenses) which may be paid for a Share is the higher of: (i) an amount equal to 105% of the average of the middle market quotations for the Shares as derived from the Daily Official List of the London Stock Exchange plc for the five business days immediately preceding the day on which the purchase is made; and (ii) an amount equal to the higher of the price of the last independent trade of a Share and the highest current independent bid for a Share on the trading venue where the purchase is carried out; and
 - 19.4 the Company shall be entitled, before the expiry of this authority, to enter into any contract to purchase Shares before the expiry of this authority under which such purchase will or may be completed or executed wholly or partly after this authority expires and may make a purchase of Shares pursuant to any such contract as if this authority had not expired.
20. That, as permitted by section 307A of the 2006 Act, any general meeting of the Company (other than an Annual General Meeting of the Company) may be called by notice of not less than 14 clear days in accordance with the provisions of the Articles of Association of the Company, provided that this authority shall expire at the conclusion of the next Annual General Meeting of the Company.
21. That:
- (a) the rules of the Dechra 2021 Deferred Bonus Plan (the 2021 DBP), in the form produced to the Meeting and initialled by the Chairman of the Meeting for the purposes of identification and the principal terms of which are summarised in the Appendix to the circular containing the Company's 2021 Notice of Annual General Meeting, be and they are hereby approved and the Directors be and are generally authorised to adopt the 2021 DBP and to do all acts and things that they consider necessary or expedient to give effect to the 2021 DBP; and
 - (b) the Directors be and are hereby authorised to adopt further schemes based on the 2021 DBP but modified to take account of local tax, exchange control or securities laws in overseas territories, provided that any shares made available under such further schemes are treated as counting against any limits on individual or overall participation in the 2021 DBP.

By order of the Board

Melanie Hall

Company Secretary

10 September 2021

Registered office:
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

Registered in England and Wales, No. 3369634

APPENDIX

SUMMARY OF THE PRINCIPAL TERMS OF THE DECHRA 2021 DEFERRED BONUS PLAN

The Dechra 2021 Deferred Bonus Plan (the 2021 DBP) is a discretionary share plan under which the deferred part of any bonus may be delivered. The 2021 DBP will be administered by the Board of Directors or a committee appointed by the Board, and references in this summary to the Board should be read accordingly. Decisions in relation to the participation in the 2021 DBP by Executive Directors of the Company will be taken by the Remuneration Committee of the Board of Directors.

Eligibility

Any current or former employee (including an Executive Director) of the Company or any of its subsidiaries will be eligible to participate in the 2021 DBP at the discretion of the Board.

Form of Award

An award under the 2021 DBP may be granted in the form of:

- (a) a conditional right to acquire ordinary shares in the Company (Shares) at no cost (a Conditional Award); or
- (b) an option to acquire Shares at no cost or for an exercise price per Share equal to the nominal value of a Share (a Nil-Cost Option).

In this summary, Nil-Cost Options and Conditional Awards are together referred to as "Awards".

Grant of Awards

The Board may determine that a proportion of an employee's bonus will be deferred into an Award. Deferral of Executive Directors' bonuses into Awards will be in line with the Company's Directors' Remuneration Policy. The number of Shares subject to an Award will be such number of Shares as have a value (as determined by the Board) equal to the deferred bonus. Ordinarily, Awards may be granted within the six week period following announcement of the Company's results for any period or the determination of the amount of any relevant bonus. However, the Board may grant Awards at other times in exceptional circumstances. If Awards cannot be granted in any of these periods due to regulatory restrictions, they may be granted within the six week period following the lifting of the restriction.

Overall limits

Awards may be granted over newly issued Shares, treasury Shares or Shares purchased in the market.

In any ten year period, the number of Shares which may be issued under the 2021 DBP and under any other employees' share plan adopted by the Company may not exceed 10% of the issued ordinary share capital of the Company from time to time.

In any ten year period, the number of Shares which may be issued under the 2021 DBP and under any other discretionary employees' share plan adopted by the Company may not exceed 5% of the issued ordinary share capital of the Company from time to time.

Treasury Shares will be treated as newly issued for the purpose of this limit until such time as guidelines published by institutional investor representative bodies determine otherwise.

Vesting and exercise

Awards will usually vest on the second anniversary of the determination of the relevant bonus (or on such other date as the Board determines). Nil-Cost Options will then normally be exercisable until the tenth anniversary of the grant date.

Dividends

On the vesting of an Award (or on the exercise of an Award granted in the form of a Nil-Cost Option), the Company may provide additional Shares to the participant based on the value of dividends paid over such period as the Board may determine (ending no later than the vesting date). The Board shall determine the basis on which this amount is calculated which may assume the reinvestment of the dividends into Shares.

Settlement of Awards

Before Shares have been delivered, the Board may decide to pay a cash amount equal to the value of some or all of the Shares the participant would otherwise have received, although the Board would only settle an Executive Director's award in cash in appropriate circumstances such as where there is a regulatory restriction on the delivery of Shares or in respect of the tax arising on the settlement.

Malus and Clawback

At any time prior to the second anniversary of the payment of the cash part of the bonus, the Board may reduce the number of Shares to which the associated Award relates or impose further conditions on it (if Shares have not been delivered in respect of it) or may require the participant to make a payment to the Company in respect of some or all of the Shares acquired.

These malus and clawback provisions may be applied in the event of a material misstatement of the Company's financial statements, if an annual bonus award has paid out at a higher level than would have been the case but for a material misstatement or serious reputational damage, gross misconduct on the part of the participant or a material corporate failure.

Cessation of Employment – Unvested Awards

If a participant ceases employment for any reason other than their dismissal for gross misconduct (in which case their Award will lapse), their Award will continue and vest in full at the originally anticipated vesting date. The Board will, however, have discretion to vest the award at the date of cessation if the cessation is due to ill-health or otherwise in exceptional circumstances. If a participant dies, their Award will vest in full as soon as reasonably practicable after the date of death, unless the Board determines otherwise.

Corporate Events

In the event of a change of control of the Company, unvested Awards will vest in full. Alternatively, the Board may permit participants to exchange Awards for equivalent awards which relate to shares in a different company. If the change of control is an "internal reorganisation", participants will be required to exchange their Awards (rather than the Awards vesting), unless the Board determines otherwise.

If other events occur such as a winding-up of the Company, demerger, delisting, special dividend or other event which, in the opinion of the Board, may affect the current or future value of Shares, the Board may determine that Awards will vest.

Adjustment of Awards

In the event of a variation of the Company's share capital, the number of Shares subject to an Award may be adjusted.

The number of Shares subject to an Award may also be adjusted in the event of a demerger, delisting, special dividend, rights issue or other event, which may, in the Board's opinion, affect the current or future value of Shares.

Amendment, Termination and Further Terms of the 2021 DBP

The Board may amend the 2021 DBP at any time, provided that the approval of the Company's shareholders in a general meeting will be required for any amendments to the advantage of participants relating to eligibility, limits, the basis for determining a participant's entitlement to, and the terms of, the Shares or cash comprised in an Award and the impact of any variation of capital to become effective.

However, any minor amendment to benefit administration, to take into account legislative changes, or to obtain or maintain favourable tax treatment, exchange control or regulatory treatment may be made by the Board without shareholder approval.

The 2021 DBP will usually terminate on the tenth anniversary of its approval by shareholders but the rights of existing participants will not be affected by any termination.

Awards are not transferable (other than on death). No payment will be required for the grant of an Award. Awards will not form part of pensionable earnings.

Notes:

Entitlement to attend and vote

1. The right to vote at the Meeting is determined by reference to the Register of Members. Only those shareholders registered in the Register of Members of the Company as at 6.30 pm on 19 October 2021 (or, if the Meeting is adjourned, 6.30 pm on the date which is two days before the date of the adjourned meeting) shall be entitled to attend and vote or vote by proxy at the Meeting in respect of the number of shares registered in their name at that time. Changes to entries in the Register of Members after that time shall be disregarded in determining the rights of any person to attend and vote or vote by proxy (and the number of votes they may cast) at the Meeting.

Attending in person

2. Should you wish to attend the Meeting and vote in person, please pre-register your intention to attend by emailing companysecretarial@dechra.com by 15 October 2021 (please state "Dechra Pharmaceuticals PLC: AGM" in the subject line of the email). Please include your full name and shareholder reference number, which can be found on the proxy card, your share certificate or on the Equiniti Portal. This will enable us to put in place the requisite measures which we may need to introduce to meet any potential government-mandated Covid-19 restriction. We may ask you to complete a visitor questionnaire which includes a self-declaration that you have either had two vaccinations at least two weeks before the Meeting or can show that you have a negative lateral flow test no older than 48 hours before the Meeting or a positive PCR test within the past six months before the meeting.

The impact of the pandemic will be continuously monitored, and shareholders should monitor the Company's website (www.dechra.com/investors/shareholder-information/shareholder-meetings) and regulatory news announcements for any Meeting updates.

This year we will be offering an online Annual General Meeting experience for the first time. You will have the opportunity to listen to the proceedings of the Meeting via https://brrmedia.news/Dechra_AGM21. Please note that joining remotely via https://brrmedia.news/Dechra_AGM21 does not constitute attendance at the Meeting and you will not be able to vote at the Meeting. Therefore you should submit your votes via proxy in accordance with notes 3 to 10 to this Notice.

Proxies

3. A shareholder is entitled to appoint another person as his or her proxy to exercise all or any of his or her rights to attend, speak and vote at the Meeting. A proxy need not be a shareholder of the Company.

A shareholder may appoint more than one proxy in relation to the Meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. Failure to specify the number of shares each proxy appointment relates to or specifying a number which when taken together with the numbers of shares set out in the other proxy appointments is in excess of the number of shares held by the shareholder may result in the proxy appointment being invalid. To appoint more than one proxy, complete a separate proxy form in relation to each appointment. You may photocopy the Proxy Form provided or, alternatively, you may wish to contact the Company's Registrar, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA or call their shareholder helpline on 0371 384 2030. Overseas shareholders should call +44 (0)121 415 7047. Lines are open 8.30 am to 5.30 pm, Monday to Friday, (London time) (except UK public holidays).

A proxy may only be appointed in accordance with the procedures set out in these notes and the notes to the Proxy Form. The notification of termination of a proxy appointment should be in writing.

The appointment of a proxy will not preclude a shareholder from attending and voting in person at the Meeting. Please refer to note 2 to this Notice.

4. A Proxy Form is enclosed. **To be valid, a Proxy Form must be completed, signed and sent to the offices of the Company's Registrar, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, so as to arrive no later than 9.30 am on 19 October 2021** (or, if the Meeting is adjourned, no later than 48 hours before the time of any adjourned meeting).
5. As an alternative to completing the hard copy Proxy Form, a shareholder may appoint a proxy or proxies electronically by lodging a Proxy Form at www.sharevote.co.uk. Alternatively, shareholders who have already registered with Equiniti's online portfolio service, Shareview, can vote by logging on to their portfolio at www.shareview.co.uk and then clicking on the link to vote. **For an electronic proxy appointment to be valid, the appointment must be received by Equiniti Limited no later than 9.30 am on 19 October 2021** (or, if the Meeting is adjourned, no later than 48 hours before the time of any adjourned meeting). Any electronic communication sent by a shareholder to the Company or Equiniti Limited which is found to contain a virus will not be accepted by the Company.
6. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

Appointment of proxies through CREST

Alternatively, if you are a member of CREST, you may register the appointment of proxy by using the CREST electronic proxy appointment services as follows:

7. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the Meeting and any adjournment(s) thereof by using the procedures, and to the address, described in the CREST Manual subject to the provisions of the Company's Articles of Association. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
8. In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear UK and Ireland's specifications and must contain the information required for such instruction as described in the CREST Manual (www.euroclear.com). **The message, regardless of whether it relates to the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID RA19) by no later than 9.30 am on 19 October 2021** (or, if the Meeting is adjourned, no later than 48 hours before the time of any adjourned meeting). For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Applications Host) from which issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
9. CREST members and, where applicable, their CREST sponsors, or voting service provider(s) should note that Euroclear UK and Ireland does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that their CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
10. The Company may treat a CREST Proxy Instruction as invalid in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Corporate representatives

11. Any corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member, provided that they do not do so in relation to the same shares.

Total voting rights

12. As at 9 September 2021 (being the last practicable date before the publication of this Notice), the Company's issued share capital consists of 108,217,639 ordinary shares of £0.01 each, carrying one vote each. The Company does not hold any ordinary shares in treasury. Therefore, the total voting rights in the Company as at 9 September 2021 are 108,217,639.

Nominated Persons

13. Where a copy of this notice is being received by a person who has been nominated to enjoy information rights under section 146 of the 2006 Act (Nominated Person):
 - 13.1 the Nominated Person may have a right under an agreement between him/her and the shareholder by whom he/she was nominated, to be appointed, or to have someone else appointed, as a proxy for the Meeting; or
 - 13.2 if the Nominated Person has no such right or does not wish to exercise such right, he/she may have a right under such an agreement to give instructions to the shareholder as to the exercise of voting rights.

The statement of the rights of shareholders in relation to the appointment of proxies in note 3 to 10 above do not apply to a Nominated Person. The rights described in such notes can only be exercised by shareholders of the Company.

Website publication of audit concerns

14. A shareholder or shareholders who meet the qualification criteria set out in note 15 below may require the Company to publish on its website a statement setting out any matter that such shareholders propose to raise at the Meeting relating to the external audit of the Company's accounts (including the Auditor's report and the conduct of the external audit) that are to be laid before the Meeting in accordance with section 527 of the 2006 Act.

Any such request must:

- 14.1 identify the statement to which it relates, by either setting out the statement in full or, if supporting a statement requested by another shareholder, clearly identifying the statement which is being supported;
- 14.2 comply with the requirements set out in notes 15 and 16 below; and
- 14.3 be received by the Company at least one week before the Meeting.

Where the Company is required to publish such a statement on its website:

- (i) it may not require the shareholders making the request to pay any expenses incurred by the Company in complying with the request;
- (ii) it must forward the statement to the Company's external auditor no later than the time when it makes the statement available on the website; and
- (iii) the statement may be dealt with as part of the business of the Meeting.

15. In order to require the Company to publish audit concerns as set out in note 14, the relevant request must be made by:

- 15.1 a shareholder or shareholders having a right to vote at the Meeting and holding at least 5% of the total voting rights of the Company; or
- 15.2 at least 100 shareholders having a right to vote at the Meeting and holding, on average, at least £100 of paid up share capital.

For information on voting rights, including the total voting rights of the Company, see note 12 above and the website referred to in note 21 below.

16. Any request by a shareholder or shareholders to require the Company to publish audit concerns as set out in note 14:

- 16.1 may be made either:
- (i) in hard copy, by sending it to the Company Secretary, Dechra Pharmaceuticals PLC, 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich CW9 7UA; or
- (ii) in electronic form, by sending it by fax to 01606 814731, marked for the attention of the Company Secretary or by email to companysecretarial@dechra.com (please state "Dechra Pharmaceuticals PLC: AGM" in the subject line of the email);
- 16.2 must state the full name(s) and address(es) of the shareholder(s); and
- 16.3 where the request is made in hard copy form or by fax, must be signed by the shareholder(s).

Questions at the Meeting

17. Shareholders have the right to ask questions at the Meeting relating to the business being dealt with at the Meeting in accordance with section 319A of the 2006 Act. The Company must answer any such question unless:

- 17.1 to do so would interfere unduly with the preparation for the Meeting or would involve the disclosure of confidential information;
- 17.2 the answer has already been given on a website in the form of an answer to a question; or
- 17.3 it is undesirable in the interests of the Company or the good order of the Meeting that the question be answered.

If shareholders have a question for the Board, they can submit it in electronic form by sending it by email to CompanySecretarial@dechra.com (please state "Dechra Pharmaceuticals PLC: AGM" in the subject line of the email and include your Shareholder Reference Number (as detailed on your proxy card, your share certificate or on the Equiniti Portal)). Questions submitted electronically should be received by no later than 9.30am on 15 October 2021 (or, if the Meeting is adjourned, no later than 48 hours before the time of any adjourned meeting). The Board will seek to respond to questions which are put forward in advance of the Meeting during the Meeting and/or by publishing written responses on the investor website of our website after the Meeting.

18. The Company has appointed Equiniti as its Registrar to manage the shareholder register, ensure that all information held about the Company's shareholders is kept up to date, and to pay dividends. Equiniti can be contacted at: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA. Equiniti operate a shareholder helpline on 0371 384 2030. Overseas shareholders should call +44 (0)121 415 7047. Shareholders with a text phone facility should use 0371 384 2255. Overseas shareholders with a text phone facility should use +44 (0) 121 415 7028. Lines are open 8.30am to 5.30pm (London time), Monday to Friday (except UK public holidays).

Documents available for inspection

19. The following documents will be available for inspection during normal business hours at the registered office of the Company from the date of this Notice until the time of the Meeting and at DLA Piper UK LLP, 160 Aldersgate Street, London, EC1A 4HT. They will also be available for inspection at the place of the Meeting from at least 15 minutes before the Meeting until it ends:
- 19.1 Copy of the rules of The Dechra 2021 Deferred Bonus Plan
 - 19.2 Copies of the articles of association of the Company;
 - 19.3 Copies of the service contracts of the Executive Directors;
 - 19.4 Copies of the letters of appointment of the Non-Executive Directors; and
 - 19.5 Copies of the Directors' indemnities.

Biographical details of Directors

20. Biographical details of all those Directors who are offering themselves for election and/or re-election at the Meeting are set out in the Annual Report and Accounts.

Website providing information about the Meeting

21. The information required by section 311A of the 2006 Act to be published in advance of the Meeting, which includes the matters set out in this Notice and information relating to the voting rights of shareholders, is available at www.dechra.com.

Chairman

22. If the Chairman, as a result of any proxy appointments, is given discretion as to how the votes that are the subject of those proxies are cast and the voting rights in respect of those discretionary proxies, when added to the interests in the Company's shares already held by the Chairman, result in the Chairman holding such numbers of voting rights that he has a notifiable obligation under the Disclosure and Transparency Rules, the Chairman will make the necessary notifications to the Company and the Financial Conduct Authority. As a result, any member holding 3% or more of the voting rights in the Company who grants the Chairman a discretionary proxy in respect of some or all of those voting rights and so would otherwise have a notification obligation under the Disclosure and Transparency Rules, need not make a separate notification to the Company and the Financial Conduct Authority.

Communication

23. You may not use any electronic address (within the meaning of section 333(4) of the 2006 Act) provided in this Notice (or in any related documents including the Chairman's Letter and Proxy Form) to communicate with the Company for any purposes other than those expressly stated.

Online Shareholder Guide

24. The meeting will be broadcast in audio and visual format. The link for the broadcast is https://brrmedia.news/Dechra_AGM21. You will need your Shareholder Reference Number (SRN) to login followed by your PIN which is the last four digits of your SRN.

Please note that joining remotely via https://brrmedia.news/Dechra_AGM21 does not constitute attendance at the Meeting and you will not be able to vote at the Meeting. Therefore you should submit your votes via proxy in accordance with notes 3 to 10 to this Notice.



Dechra Pharmaceuticals PLC

24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

T: +44 (0) 1606 814730

F: +44 (0) 1606 814731

E: corporate.enquiries@dechra.com

www.dechra.com